Urinary N1,N12-diacetylspermine as a biomarker for pediatric cancer: a case–control study
link.springer.com shows its articles on its own site.
Read the article on link.springer.com ↗Article · Dec 2021 · 1 min read
In brief
In brief
This case-control study evaluated urinary N1,N12-diacetylspermine as a non-invasive tumor marker in 32 pediatric cancer patients versus 405 controls. DiAcSpm showed highest sensitivity for malignant lymphoma (77.8%) compared to neuroblastoma (30.8%) and leukemia (40%), with age-related baseline variations most pronounced in infants.
Written by the GCMD Library team from the article.
Abstract
Purpose
Minimally invasive examinations are particularly important in pediatric patients. Although the significance of urinary N1,N12-diacetylspermine (DiAcSpm) as a tumor marker (TM) has been reported in many types of adult cancers, its usefulness in pediatric cancers has not been reported. This may be due to urinary DiAcSpm level variations with age. This study aims to measure the normal levels of urinary DiAcSpm in healthy individuals and investigate its usefulness as a TM in childhood cancer.
Methods
Urinary samples were collected from pediatric patients with and without cancer. The urinary DiAcSpm levels were measured, and the values were compared.
Results
A total of 32 patients with cancer and 405 controls were enrolled in the study. Of the 32 patients, 13 had neuroblastoma, 9 had malignant lymphoma (ML), and 10 had leukemia. In the control group, the urinary DiAcSpm values markedly fluctuated among those with young age, especially infants; meanwhile, the values converged among those aged roughly 10 years and above. The sensitivity of DiAcSpm was significantly different among the three types of cancers: neuroblastoma (30.8%), ML (77.8%), and leukemia (40%).
Conclusion
The urinary DiAcSpm value is a useful TM for both screening and follow-up of ML.